Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
6.12
Dollar change
+0.14
Percentage change
2.43
%
IndexRUT P/E- EPS (ttm)-0.08 Insider Own5.33% Shs Outstand57.53M Perf Week-5.85%
Market Cap356.18M Forward P/E- EPS next Y-0.33 Insider Trans-3.76% Shs Float55.10M Perf Month19.77%
Income-4.89M PEG- EPS next Q- Inst Own83.33% Short Float4.52% Perf Quarter56.52%
Sales177.60M P/S2.01 EPS this Y-250.00% Inst Trans-1.99% Short Ratio0.96 Perf Half Y53.77%
Book/sh9.35 P/B0.65 EPS next Y-450.00% ROA-0.75% Short Interest2.49M Perf Year-2.08%
Cash/sh6.77 P/C0.90 EPS next 5Y36.10% ROE-0.91% 52W Range3.30 - 6.76 Perf YTD45.02%
Dividend Est.- P/FCF- EPS past 5Y-37.98% ROI-0.89% 52W High-9.47% Beta0.76
Dividend TTM- Quick Ratio4.69 Sales past 5Y1.11% Gross Margin90.32% 52W Low85.74% ATR (14)0.38
Dividend Ex-Date- Current Ratio4.71 EPS Y/Y TTM-130.09% Oper. Margin-14.18% RSI (14)58.90 Volatility6.50% 5.23%
Employees203 Debt/Eq0.02 Sales Y/Y TTM-30.81% Profit Margin-2.75% Recom2.00 Target Price5.21
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-226.86% Payout0.00% Rel Volume0.55 Prev Close5.97
Sales Surprise-2.14% EPS Surprise-240.00% Sales Q/Q-24.06% EarningsMay 08 AMC Avg Volume2.60M Price6.12
SMA209.11% SMA5018.60% SMA20040.03% Trades Volume1,422,091 Change2.43%
Date Action Analyst Rating Change Price Target Change
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Jun-21-24 07:00AM
Jun-19-24 08:48PM
Jun-13-24 09:00PM
10:02AM
Jun-07-24 06:26AM
06:02AM Loading…
06:02AM
Jun-06-24 09:24AM
08:00AM
07:38AM
May-30-24 05:20PM
04:48PM
May-29-24 02:17PM
May-24-24 04:46PM
May-16-24 11:24AM
06:22AM
01:04PM Loading…
May-15-24 01:04PM
08:45AM
May-10-24 03:24PM
May-09-24 12:37PM
06:43AM
03:38AM
May-08-24 08:58PM
04:10PM
04:01PM
May-07-24 11:33AM
11:16AM
09:22AM
09:10AM
09:00AM
Apr-30-24 04:30PM
10:45AM Loading…
Apr-25-24 10:45AM
09:00AM
08:05AM
Apr-24-24 06:00PM
01:58PM
Apr-22-24 07:13PM
04:11PM
11:37AM
10:09AM
Apr-19-24 01:06PM
Apr-18-24 09:44AM
09:00AM
Apr-17-24 02:29PM
11:53AM
10:21AM
09:11AM
09:02AM
08:32AM
06:30AM
Apr-15-24 06:00PM
Apr-10-24 06:15PM
Apr-04-24 07:52AM
Apr-03-24 12:02PM
10:48AM
10:00AM
Apr-02-24 06:10PM
Mar-07-24 10:47AM
Mar-06-24 11:55PM
07:00AM
Feb-14-24 04:22AM
Feb-12-24 12:20PM
Feb-08-24 09:38AM
07:06AM
Feb-07-24 05:02PM
04:26PM
04:02PM
Feb-05-24 08:00AM
Jan-31-24 04:30PM
09:00AM
Jan-30-24 12:35PM
01:02AM
Jan-29-24 07:00PM
Jan-25-24 10:05PM
01:07PM
Jan-23-24 09:15AM
Jan-19-24 03:56PM
Jan-17-24 03:46PM
Jan-12-24 12:21PM
Jan-04-24 04:30PM
Dec-07-23 07:00AM
Dec-05-23 09:17AM
Dec-04-23 06:00PM
Nov-10-23 11:45AM
Nov-09-23 04:30PM
06:01AM
Nov-08-23 05:50PM
05:25PM
04:01PM
Nov-01-23 05:00PM
Oct-20-23 07:00AM
Oct-05-23 06:30PM
Sep-20-23 12:28PM
Sep-06-23 05:30PM
Sep-05-23 02:36PM
Sep-01-23 06:51PM
09:35AM
09:18AM
Aug-01-23 09:25AM
Jul-28-23 06:18AM
Jul-27-23 04:07PM
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Polymeropoulos Mihael HristosPresident and CEOMar 05 '24Sale4.1324,288100,2731,871,730Mar 06 04:47 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 05 '24Sale4.219,22938,830129,789Mar 06 04:48 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 05 '24Sale4.208,90237,411231,014Mar 06 04:46 PM
Williams TimothySVP & General CounselMar 05 '24Sale4.188,94137,396196,825Mar 06 04:50 PM
Birznieks GuntherSVP, Business DevelopmentMar 05 '24Sale4.138,68435,884313,569Mar 06 04:46 PM
Polymeropoulos Mihael HristosPresident and CEOMar 04 '24Sale4.2430,884131,0661,896,018Mar 06 04:47 PM
Birznieks GuntherSVP, Business DevelopmentMar 04 '24Sale4.308,72737,495322,253Mar 06 04:46 PM
Williams TimothySVP & General CounselMar 04 '24Sale4.418,14735,917205,766Mar 06 04:50 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 04 '24Sale4.417,49833,091139,018Mar 06 04:48 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 04 '24Sale4.485,79825,982239,916Mar 06 04:46 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 21 '23Sale5.843,72421,748113,816Aug 23 04:23 PM
Mitchell Stephen RayDirectorAug 10 '23Sale6.056,50039,34929,328Aug 11 04:36 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 28 '23Sale6.302,21213,945120,714Aug 01 04:30 PM